Reimagine the Power of

Targeted Therapies

Significantly Improving Upon the Delivery, Safety and Performance of Cancer Therapeutics.

Transforming Cancer Therapy

NanoValent Pharmaceuticals is a privately-held company, collaborating closely with Children’s Hospital Los Angeles (CHLA) as well as other US-based academic partners. We’re dedicated to creating novel treatment options designed to bring us closer to a potential cure for hard to treat cancers.

Now seeking Series A finance in 2025 NanoValent Pharmaceuticals possesses a highly experienced core management team with a proven track record of success, supported by a strong clinical and operational capability.

Using our unique, highly optimized Hybrid Polymerized Liposomal Nanoparticle (HLPN) platform technology, we create Novel Format Conjugates called nano-ADCs (nADC)or Targeted Nanosphers (TNS). These targeted agents significantly improve the delivery, safety and efficacy of both existing and novel anti-cancer therapeutics

Nano-ADCs are created using our highly flexible platform technology. The power of this platform technology is best demonstrated by our lead investigational product, NV103, which os approaching potential IND status with strong data in CD19 expressing tumor models, including Glioblastoma, Pancreatic, Ovarian and Ewing Sarcoma.

Innovative Medicine

Based on our unique platform technology, we develop novel, targeted drugs that more precisely target malignant cells while sparing normal, healthy tissues. Due to their capacity to cross the blood-brain barrier (BBB), nano-ADCs (nADC) or Targeted Nanospheres (TNS), based on our platform technology, can be applied beyond oncology, including neurology

Unmet Medical Needs

Despite important advances in available treatments for oncological and hematological malignancies, there remain unmet medical needs requiring the development of novel targeted therapies. Unlocking the power of these therapies, including antibody-drug conjugates (ADCs), has resulted in novel tools, allowing tumor specific targeting. However, the performance of these targeted therapeutics remains limited, resulting in many patients unable to benefit.

Our Pipeline

Using our unique, highly optimized Hybrid Polymerized Liposomal Nanoparticle (HPLN) platform technology, we have developed tumor-specific targeted novel format conjugates called nano-ADCs (nADC) or Targeted Nanospheres (TNS) which combine drug-loaded nanoparticles with the targeting ability of monoclonal antibodies.

The resulting technology offers several significant advantages over existing untargeted and targeted therapies.

Our Science

NV101 (Doxorubicin-anti CD99)

Validating programs with NV101 in Ewing Sacroma and CD99 expressing tumors are planned.

NV102 (Doxorubicin-anti CD19)

Validating programs with NV102 in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and other CD19 expressing tumors are planned.

NV103 (Irinotecan-anti-CD99)

NV103, our lead product, is now approaching Investigational News Drug Application (IND) status and being validated in CD99 expressing tumors, including Glioblastoma, Pancreatic cancer, Ovarian cancer and Ewing Sarcoma.

Outperforming ADCs

Our Platform technology allows for preferentially delivery of cytotoxic drugs to cancer cells while sparing normal, healthy cells and tissue.

Improving on the high tumor specificities already seen with ADCs, our novel format nano-ADCs (nADC) or Targeted Nanosphers (TNS) provide a significantly greater on-target drug-to-antibody ratio (DAR) than ADCs (several thousand cytotoxic drug molecules per nanoparticle-conjugated antibody versus only 2 to 8 conjugated drug molecules per ADC).

Furthermore, the polyvalency of multiple antibodies attached to a single nano-ADC (nADC) or Targeted Nanosphers (TNS) enhances the overall avidity of nanoparticles to target tumor cells, compared to a single ADC.

Finally, the cytotoxic agents inside the hollow-shell nanoparticle are not chemically conjugated to the carrier. Once released from the carrier, no in situ chemical decoupling is required for the drug to become fully bioavailable.